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in non-Hodgkin and Hodgkin lymphomas
Zhaohui Wang1,2†, Lili Li1,2†, Xianwei Su2, Zifen Gao3, Gopesh Srivastava4, Paul G Murray5, Richard Ambinder6
and Qian Tao1,2,6*Abstract
Background: Inactivaion of tumor suppressor genes (TSGs) by promoter CpG methylation frequently occurs in
tumorigenesis, even in the early stages, contributing to the initiation and progression of human cancers. Deleted in
lung and esophageal cancer 1 (DLEC1), located at the 3p22-21.3 TSG cluster, has been identified frequently silenced
by promoter CpG methylation in multiple carcinomas, however, no study has been performed for lymphomas yet.
Methods: We examined the expression of DLEC1 by semi-quantitative reverse transcription (RT)-PCR, and evaluated
the promoter methylation of DLEC1 by methylation-specific PCR (MSP) and bisulfite genomic sequencing (BGS) in
common lymphoma cell lines and tumors.
Results: Here we report that DLEC1 is readily expressed in normal lymphoid tissues including lymph nodes and
PBMCs, but reduced or silenced in 70% (16/23) of non-Hodgkin and Hodgkin lymphoma cell lines, including 2/6
diffuse large B-cell (DLBCL), 1/2 peripheral T cell lymphomas, 5/5 Burkitt, 6/7 Hodgkin and 2/3 nasal killer (NK)/T-cell
lymphoma cell lines. Promoter CpG methylation was frequently detected in 80% (20/25) of lymphoma cell lines and
correlated with DLEC1 downregulation/silencing. Pharmacologic demethylation reversed DLEC1 expression in
lymphoma cell lines along with concomitant promoter demethylation. DLEC1 methylation was also frequently
detected in 32 out of 58 (55%) different types of lymphoma tissues, but not in normal lymph nodes. Furthermore,
DLEC1 was specifically methylated in the sera of 3/13 (23%) Hodgkin lymphoma patients.
Conclusions: Thus, methylation-mediated silencing of DLEC1 plays an important role in multiple lymphomagenesis,
and may serve as a non-invasive tumor marker for lymphoma diagnosis.
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Epigenetic silencing of tumor suppressor genes (TSGs)
by promoter CpG methylation and histone modification
has been widely recognized as one of the major causes
of tumorigenesis including hematological malignancies
[1,2]. Aberrant methylation of TSG is frequently* Correspondence: qtao@clo.cuhk.edu.hk
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reproduction in any medium, provided the ordetected even in the early stage of tumorigenesis, sug-
gesting its potential as tumor biomarker for early detec-
tion and therapeutic targeting.
Deletions of the 3p22-21.3 region have been identified
as one of the earliest molecular events in various malig-
nancies [3], including naspharyngeal [4], head and neck
[5], lung [6], gastric [7], breast [8], cervix [9] and renal
[10] carcinomas, as well as lymphomas [11]. A growing
number of TSGs, including RASSF1A [12,13], BLU/
ZMYND10 [14,15], and CACNA2D2 [16], have been
identified in this region [17,18]. Frequent inactivation of
several 3p21.3 genes as functional TSGs, such as
RASSF1 and BLU [14,19], by promoter CpG methylation
had been identified associated with tumor initiation andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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RASSF1A has been shown related to poor prognosis and
advanced tumor stage of certain tumor types [20-33].
Restoration of RASSF1A in cancer cell lines inhibited
tumor cell growth and metastasis [34]. Thus, 3p22-21.3
is a critical TSG cluster in tumorigenesis [3,18].
Deleted in lung and esophageal cancer 1 (DLEC1), a
3p22 cluster genes, was first identified as a TSG in
esophageal and lung cancers [35]. Downregulation of
DLEC1 by promoter methylation has been found in mul-
tiple cancers, including nasopharyngeal [36,37], ovarian
[38], lung [39], hepatocellular [40], gastric [41], renal
[42], and breast carcinomas [43], suggesting its potential
as a broad TSG [44,45]. Remarkably, DLEC1 was methy-
lated in breast cancer as well as pre-invasive lesions but
rarely in normal breast tissues, indicating its potential as
an epigenetic marker for early tumors [43].
In this study, we examined the expression and methy-
lation status of DLEC1 in lymphoma cell lines and tis-
sues, and evaluated its potential as a tumor marker for
the early detection of hematologic tumors.
Methods
Cell lines and tumor samples
Non-Hodgkin and Hodgkin lymphoma cell lines studied
included diffuse large B-cell lymphoma (DLBCL) cell
lines (OCI-Ly1, Ly3, Ly7, Ly8, Ly18, SUDHL6); periph-
eral T cell lymphoma (PTCL) cell lines (Ly13.2, Ly17);
Burkitt lymphoma (BL) cell lines (AG876, BJAB,
Namalwa, Rael, Raji); Hodgkin lymphoma (HL) cell lines
(L428, L540, L591, L1236, KM-H2, HD-LM-2, HD-MY-Z)
(DSMZ cell collection, Braunschweig, Germany); and nat-
ural killer (NK)/T-cell lines (NL) (KHYG-1, SNK6, YT)
[46-48]. Cell lines were maintained in RPMI1640 orFigure 1 DLEC1 is downregulated in lymphoma cell lines. A. Expressio
samples. B. Representative analyses of DLEC1 expression by RT-PCR in lymp
marrow; DLBCL: diffuse large B-cell lymphoma; PTCL: peripheral T cell lymp
nasal NK/T-cell lymphoma.Dulbecco’s Modified Eagle’s Medium supplemented with
10% fetal calf serum (FBS) (Invitrogen, Paisley, Scotland)
and 1% streptomycin/penicillin at 37°C in 5% CO2. HL cell
lines were treated with 5 μM of 5-aza-20-deoxycytidine
(Aza) (Sigma) for 3 days, or further treated with
100 nmol/L trichostatin A (Cayman Chemical Co., Ann
Arbor, MI, USA) for additional ~16 h as described previ-
ously [15,49], and L428 and KM-H2 cell lines were treated
with Aza for 6 days.
Normal peripheral blood mononuclear cells (PBMC),
lymph node samples, different types of lymphoma sam-
ples, as well as sera from healthy individuals and HL
patients were collected as previously described, and the
reliability and quality of all the studied samples in this
study have been confirmed before [41,47,50]. The study
was approved by Johns Hopkins Medicine Institutional
Review Board. Normal adult tissue RNA samples were
purchased commercially (Stratagene, La Jolla, CA, USA
or Millipore-Chemicon, Billerica, MA, USA). DNA and
RNA were extracted from lymphoma cell lines and pri-
mary lymphomas using TRIzol reagent (Invitrogen) as
previously described [51,52].
Semi-quantitative reverse transcription (RT)-PCR
RT-PCR was performed as previously described [40,41].
Primers used for RT-PCR are: DLEC1A: 50-ttcctccctcg
cctactc, DLEC1B: 50-aaactcatccagccgctg; GAPDH33: 50-ga
tgaccttgcccacagcct, GAPDH55: 50-atctctgccccctctgctga.
RT-PCR was done with 32 cycles for DLEC1 and 23 cycles
for GAPDH.
Bisulfite treatment and promoter methylation analysis
Bisulfite modification of DNA, methylation-specific PCR
(MSP) and bisulfite genomic sequencing (BGS) weren analysis of DLEC1 in normal adult tissues, lymph nodes, and PBMC
homa cell lines. GAPDH was used as internal control. B.M: bone
homa; BL: Burkitt lymphoma; HL: Hodgkin lymphoma; NL:
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were: DLEC1m1: 50-gtttcgtagttcggtttcgtc; DLEC1m2:
50-cgaaatatcttaaatacgcaacg; DLEC1u1: 50-tagttttgtagtttggt
tttgtt; DLEC1u2: 50-acaaaatatcttaaatacacaaca. For BGS,
bisulfite-treated DNA was amplified using primers
DLEC1BGS1: 50-gaagatataaatgtttataatgatt; DLEC1BGS4:Figure 2 Promoter CpG methylation of DLEC1 in lymphoma cell lines.
rectangle), and CpG sites (short vertical lines). Numbers from 1 to 61 indica
in lymphoma cell lines. M: methylated; U: unmethylated; DLBCL: diffuse larg
nasal NK/T-cell lymphoma. C. High resolution mapping of the methylation
representative BL and HL cell lines. The DLEC1 transcription start site is sho
individual promoter allele that was cloned, randomly selected, and sequen
CpG site.50-aactacaaccccaaatcctaa. ANKRD30Am1: 50-cggtagttgtta
tttgtacgc; ANKRD30Am2: 50-tcctctctcaataaaatcgcg. MSP
and BGS were performed for 40 cycles by using the
AmpliTaq-Gold DNA polymerase (Applied Biosystems).
All primer sets were previously tested for not amplifying
any unbisulfited DNA. Amplified BGS products wereA. Diagram shows the DLEC1 CpG island, exon 1 (indicated with a
te the individual CpG sites. B. DLEC1 methylation as measured by MSP
e B-cell lymphoma; BL: Burkitt lymphoma; HL: Hodgkin lymphoma; NL:
status of the DLEC1 promoter by BGS in normal PBMCs, and
wn as bent arrows. Circles, CpG sites analyzed; row of circles, an
ced; filled circle, methylated CpG site; open circle, unmethylated
Table 1 Frequencies of DLEC1 methylation in various
lymphoma tissues
Lymphoma DLEC1 promoter
(methylated)
Cell lines Diffuse large B‑cell lymphoma 50% (3/6)
Peripheral T-cell lymphoma 50% (1/2)
Burkitt lymphoma 100% (5/5)
Hodgkin lymphoma 100% (7/7, one weak)
Nasal NK/T-cell lymphoma 67% (2/3)
Tumors Burkitt lymphoma 83% (5/6)
Diffuse large B‑cell lymphoma 10% (1/10)
Nasal NK/T‑cell lymphoma 75% (6/8)
Hodgkin lymphoma 53% (16/30, one weak)
Follicular lymphoma 100% (4/4, two weak)
HL sera 23% (3/13)
Normal samples Normal lymph node 0/9
Normal sera 0/20
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sequencing.
Results
DLEC1 was downregulated by promoter CpG methylation
in lymphoma cell lines
We first examined the expression of DLEC1 mRNA in
25 non-Hodgkin and Hodgkin lymphoma cell lines by
RT-PCR. DLEC1 was highly expressed in the normal
lymph node, PBMC samples, as well as human adult
testis and bone marrow tissues (Figure 1A), but silenced
or reduced in 33% (2/6) DLBCL, 50% (1/2) PTCL, 100%
(5/5) BL, 86% (6/7) HL, and 67% (2/3) NL cell lines
(Figure 1B), indicating that DLEC1 is a candidate TSG
for lymphomas.
The promoter and exon 1 region of DLEC1 is a typical
CpG island, with a T/C SNP site at CpG#29 (Figure 2A).
MSP analysis showed that DLEC1 promoter methylation
was frequently detected in 3/6 DLBCL, 1/2 PTCL, 5/5
BL, 7/7 (one weak) HL, and 2/3 NL cell lines (Figure 2B;
Table 1), well correlated with its silencing or reduction.
DLEC1 methylation was further verified in detail by BGS
analysis of 61 CpG sites within the CpG island. CpG
sites of DLEC1 examined were heavily methylated in BL
cell lines Rael, Raji, and in the HL cell line L428, but
rarely in all normal PBMC samples, which confirmed
the MSP data (Figure 2C). These results indicate that
DLEC1 silencing by promoter methylation is a critical
event in lymphomagenesis.
Silencing of DLEC1 could be reversed by pharmacologic
demethylation
To further confirm whether promoter methylation med-
iates the loss of DLEC1 expression in lymphoma, lymph-
oma cell lines with methylated and reduced DLEC1 were
treated with the DNA methylation inhibitor, Aza, alone
or combined with the HDAC inhibitor trichostatin A
(TSA). After Aza treatment, DLEC1 expression was sig-
nificantly induced in cell lines Rael, L428, L1236 and
KM-H2. MSP analysis showed increased unmethylated
alleles. Similar results were obtained using a combination
treatment of Aza and TSA (Figure 3). Demethylation of
the DLEC1 promoter was further confirmed by BGS.
These results confirmed that promoter CpG methylation
directly mediates DLEC1 silencing in lymphomas.
DLEC1 is frequently methylated in primary lymphomas
We next investigated DLEC1 methylation in different
types of primary lymphomas. Of 58 lymphoma tissues,
DLEC1 methylation was detected in 5/6 (83%) BL, 16/30
(53%, one weak) HL, 1/10 (10%) DLBCL, 6/8 (75%) NL,
and 4/4 (100%, two weak) follicular lymphoma (FL)
tumor samples, while no methylation was detected in
normal lymph node samples (Figure 4A and B; Table 1).Unmethylated bands were detected in all samples due to
the inevitable inclusion of non-tumor cells in the analysis.
Furthermore, the reduction or silencing of DLEC1 expres-
sion was observed in 6 out of 7 (86%) NL tumors as mea-
sured by RT-PCR.
Furthermore as a pilot study, we examined DLEC1
methylation in serum samples of 13 HL patients with
sera from 20 healthy individuals as controls. ANKRD30A
is a normally methylated gene, thus used as an internal
control for validating genomic DNA integrity of these
samples, in addition to unmethylated DLEC1. Results
showed that DLEC1 methylation was detected in 3/13
(23%) sera from HL patients (Figure 4D) but not in any
normal sera.
Discussion
DLEC1 is located in the commonly deleted region 3p22-
21.3 [3,18]. A cluster of TSGs, including RASSF1A, BLU,
and CACNA2D2, has been identified within this region.
Silencing of RASSF1A, BLU, as well as DLEC1 by pro-
moter CpG methylation had been extensively identified in
multiple human cancers. Notably, promoter methylation
of several 3p22-21.3 TSGs, such as RASSF1A and BLU,
has also been identified in lymphomas [50,55], suggesting
that TSGs in this region are frequently susceptible to
epigenetic disruption during lymphoma pathogenesis.
Here, we report that DLEC1 is frequently silenced by
promoter methylation both in lymphoma cell lines and
primary lymphomas, but seldom in normal lymph nodes
and PBMCs. Pharmacologic demethylation could reacti-
vate DLEC1 expression, suggesting that epigenetic
mechanism including DNA methylation and histone
modification mediates DLEC1 transcriptional silencing.
As primary tumor tissues usually contain infiltrating
Figure 3 Pharmacologic demethylation restored DLEC1 expression in methylated/silenced lymphoma cell lines. A. Expression and
methylation analyses of DLEC1 in HL cell lines with Aza treatment or combined with TSA (A+T). M: methylated; U: unmethylated. B. BGS analysis
of DLEC1 methylation in lymphoma cell line KM-H2 before and after 5 μM Aza treatment.
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alleles were detected in all the tumor samples which also
acting as an internal control for genomic DNA integrity.
DLEC1 unmethylated alleles and ANKRD30A methy-
lated alleles detected in different types of normal andFigure 4 DLEC1 is frequently methylated in lymphoma tissues. A. MSP
Templates used for positive controls are: bisulfite treated DNA from HCT11
SW480 (+ve-control1) and SNU16 (+ve-control2) cell lines for unmethylatio
lymphomas by MSP in primary lymphoma BL, DLBCL, HL and FL samples. B
Hodgkin lymphoma; NL: nasal NK/T-cell lymphoma; FL: follicular lymphoma
was used as an internal control. D. Representative MSP analysis of DLEC1 m
Positive controls: bisulfite treated DNA from HCT116 (+ve-control1) and HTlymphoma samples indicated the reliability of these sam-
ples as shown before. DLEC1 methylation showed a rela-
tively low frequency in DLBCL samples, compared to
other lymphoma types. The reason for this difference is
not clear probably due to the special biologic features ofanalysis of DLEC1 methylation in normal lymph node samples.
6 (+ve-control1) and HT-29 (+ve-control2) cell lines for methylation;
n. B. Representative analyses of DLEC1 methylation in primary
L: Burkitt lymphoma; DLBCL: diffuse large B-cell lymphoma; HL:
. C. Representative analysis of DLEC1 expression in NL tumors. GAPDH
ethylation in serum samples from HL patients and normal controls.
-29 (+ve-control2) cell lines. M: methylated; NS: non-specific band.
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sample size. Our results suggest that epigenetic silencing
of DLEC1 is important for lymphoma pathogenesis. Re-
markably, DLEC1 is specifically methylated in sera of HL
patients, suggesting its potential as an epigenetic bio-
marker for the non-invasive diagnosis of lymphomas.
Conclusions
This study identifies the frequent epigenetic inactivation
of DLEC1 in various lymphomas and demonstrates its
potential as a non-invasive tumor marker for the detec-
tion of lymphomas. More molecular studies on the
tumor suppressive functions of DLEC1 in lymphoma
pathogenesis are needed.
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